Perrigo Company and Paddock Laboratories, Inc.
The FTC required generic drug manufacturers Perrigo Company and Paddock Laboratories, Inc. to divest six generic drugs as a condition of resolving charges that Perrigo's $540 million acquisition of Paddock would be anticompetitive. The settlement included specific provisions to preserve future competition in the market for generic testosterone gel. A modified final order issued on June 26, 2012 directed the companies to sell the six generic drugs to Watson Pharmaceuticals, Inc.
Required actions (3)
required generic drug manufacturers Perrigo Company and Paddock Laboratories, Inc. to sell six generic drugs under a proposed settlement resolving charges that Perrigo's proposed $540 million acquisition of Paddock would be anticompetitive
The proposed settlement also contains provisions to ensure future competition in the market for generic testosterone gel product.
the FTC issued a modified final order that required the companies to sell six generic drugs to Watson Pharmaceuticals, Inc.
Does your site contain similar claims?
The free site audit scans your whole site against every entry in this Atlas. Most trt sites match 3-6 patterns.
Run my free site auditWorried about one specific page, ad, or email? Paste it into the free Claim Checker and see what the FDA and FTC would flag, with the precedent next to each one. No email required.
Check specific copy in the Claim Checker